|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL34 |
Gene summary for MRPL34 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL34 | Gene ID | 64981 |
| Gene name | mitochondrial ribosomal protein L34 | |
| Gene Alias | L34mt | |
| Cytomap | 19p13.11 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | A0A024R7J4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64981 | MRPL34 | GSM4909285 | Human | Breast | IDC | 4.33e-09 | 4.17e-01 | 0.21 |
| 64981 | MRPL34 | GSM4909287 | Human | Breast | IDC | 5.18e-05 | 3.90e-01 | 0.2057 |
| 64981 | MRPL34 | GSM4909290 | Human | Breast | IDC | 3.40e-21 | 7.04e-01 | 0.2096 |
| 64981 | MRPL34 | GSM4909296 | Human | Breast | IDC | 1.68e-03 | 4.66e-02 | 0.1524 |
| 64981 | MRPL34 | GSM4909297 | Human | Breast | IDC | 1.88e-08 | -8.72e-02 | 0.1517 |
| 64981 | MRPL34 | GSM4909308 | Human | Breast | IDC | 3.41e-06 | 3.82e-01 | 0.158 |
| 64981 | MRPL34 | GSM4909311 | Human | Breast | IDC | 2.68e-15 | -1.96e-01 | 0.1534 |
| 64981 | MRPL34 | GSM4909312 | Human | Breast | IDC | 7.47e-07 | -6.68e-02 | 0.1552 |
| 64981 | MRPL34 | GSM4909319 | Human | Breast | IDC | 1.43e-23 | -1.17e-01 | 0.1563 |
| 64981 | MRPL34 | GSM4909320 | Human | Breast | IDC | 8.79e-15 | 5.84e-01 | 0.1575 |
| 64981 | MRPL34 | GSM4909321 | Human | Breast | IDC | 9.81e-22 | 4.75e-01 | 0.1559 |
| 64981 | MRPL34 | brca2 | Human | Breast | Precancer | 1.48e-02 | 1.84e-01 | -0.024 |
| 64981 | MRPL34 | M1 | Human | Breast | IDC | 3.23e-05 | 4.09e-01 | 0.1577 |
| 64981 | MRPL34 | NCCBC14 | Human | Breast | DCIS | 3.82e-04 | -4.14e-02 | 0.2021 |
| 64981 | MRPL34 | NCCBC5 | Human | Breast | DCIS | 2.28e-02 | -1.79e-01 | 0.2046 |
| 64981 | MRPL34 | P1 | Human | Breast | IDC | 1.80e-12 | 1.02e-01 | 0.1527 |
| 64981 | MRPL34 | DCIS2 | Human | Breast | DCIS | 5.07e-47 | 2.32e-02 | 0.0085 |
| 64981 | MRPL34 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.02e-10 | 4.79e-01 | -0.1808 |
| 64981 | MRPL34 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.49e-12 | 5.88e-01 | -0.0811 |
| 64981 | MRPL34 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.71e-21 | 6.43e-01 | -0.1954 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa030104 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa030105 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa030106 | Colorectum | MSI-H | Ribosome | 87/797 | 167/8465 | 5.55e-46 | 1.80e-43 | 1.51e-43 | 87 |
| hsa030107 | Colorectum | MSI-H | Ribosome | 87/797 | 167/8465 | 5.55e-46 | 1.80e-43 | 1.51e-43 | 87 |
| hsa0301039 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010115 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL34 | SNV | Missense_Mutation | c.22C>A | p.Leu8Met | p.L8M | Q9BQ48 | protein_coding | tolerated_low_confidence(0.16) | benign(0.125) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPL34 | SNV | Missense_Mutation | novel | c.208N>A | p.Leu70Met | p.L70M | Q9BQ48 | protein_coding | tolerated(0.07) | possibly_damaging(0.672) | TCGA-AX-A3G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| MRPL34 | SNV | Missense_Mutation | novel | c.170N>G | p.Asn57Ser | p.N57S | Q9BQ48 | protein_coding | deleterious(0.01) | probably_damaging(0.953) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| MRPL34 | SNV | Missense_Mutation | novel | c.199N>A | p.Val67Ile | p.V67I | Q9BQ48 | protein_coding | tolerated(1) | benign(0) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL34 | deletion | Frame_Shift_Del | novel | c.181delN | p.Lys61ArgfsTer10 | p.K61Rfs*10 | Q9BQ48 | protein_coding | TCGA-33-4533-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MRPL34 | SNV | Missense_Mutation | c.46N>C | p.Ala16Pro | p.A16P | Q9BQ48 | protein_coding | deleterious_low_confidence(0.01) | benign(0.029) | TCGA-BR-7197-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MRPL34 | deletion | In_Frame_Del | novel | c.178_189delNNNNNNNNNNNN | p.Arg60_Lys63del | p.R60_K63del | Q9BQ48 | protein_coding | TCGA-IN-A6RN-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |